Corporate parent
Johnson & Johnson
Johnson & Johnson is a publicly traded healthcare company. Its fiscal 2025 Form 10-K calls it a holding company whose operating companies run two continuing segments, Innovative Medicine and MedTech. It is not a private equity firm. The consumer health business was separated into Kenvue, and Johnson & Johnson owned no Kenvue shares after the fiscal second quarter of 2024. Consumer brands that left with that business are not listed as current products. Many medicines in the key-product list were developed with partners or licensed from other companies.
United States · United States · New Brunswick, New Jersey
Headquarters are New Brunswick, New Jersey. Products are sold in many countries. The United States label is that headquarters.
Current records
29 records · page 2 of 2
- STELARAPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- SYMTUZAPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- TALVEYPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- TECNISMedical devices · Healthcare
The fiscal 2025 Form 10-K lists TECNIS premium intraocular lenses in the MedTech Vision portfolio.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- TECVAYLIPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- TREMFYAPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- UPTRAVIPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- XARELTOPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. The filing says XARELTO was co-developed with Bayer HealthCare AG.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
- ZYTIGAPharmaceuticals · Healthcare
Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.
As of Dec 28, 2025. Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission
Exited or ended
- KenvuePersonal care · Healthcare
The fiscal 2025 Form 10-K says Kenvue completed an initial public offering on May 8, 2023, Johnson & Johnson disposed of a further 80.1% on August 23, 2023, and in the fiscal second quarter of 2024 it completed a debt-for-equity exchange of the retained stake. After that exchange the company owned no Kenvue shares. Consumer health results through the exchange offer are discontinued operations.
Last checked Sep 22, 2026.
- Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 · U.S. Securities and Exchange Commission